United Kingdom
Highly capable, senior pharmaceutical leader with 27+ years of pharmaceutical development experience. Strong credibility in leading drug and drug-device development programmes from early development through to commercialisation, turning around underperforming programmes and leading high-performing cross-functional teams across complex global environments. Proven ability to provide strong strategic judgement, navigate change, drive stakeholder alignment and results across diverse modalities, therapeutic areas, development stages and company types. Passionate about patient impact, team empowerment, collaboration, communication and building resilient development strategies. Core Strengths: - Cross functional leadership & stakeholder management – strong track record of managing complex internal and external relationships, including international teams, regulatory authorities, company boards and alliance partners - Demonstrated ability to turnaround underperforming programmes and redefine strategic direction - Delivery of $100m+ programmes to plan and budget - Breadth of experience from early development through to registration and life-cycle management across a range of therapeutic areas, routes of administration and device delivery mechanisms - Resilience and adaptability – navigated multiple restructures and strategic pivots showing loyalty and agility. - Experience working for small start-ups, mid-cap companies through to large international companies - Problem solving – proactive problem solver, ensuring key risks well-communicated and addressed - Committed to meeting business objectives with a proactive and positive approach and strong communication skills.
Leadership of multiple global inhaled drug-device development programmes in early and late-stage development with programme budget responsibility of $100m+ Repeatedly parachuted in to lead underperforming programmes to redefine strategic direction and improve team performance Improved team satisfaction by over 30% when took over leadership of a challenging cross-company collaboration Provided key guidance to company executive team on programme risk and development complexity which led to the business decision to end several high-risk programmes Assessment of over 400 pipeline expansion opportunities, including internal innovation and due diligence. Presentation of development strategy and business case evaluations to executive leadership team with guidance informing business portfolio strategy.
Leadership of multiple global inhaled drug-device development programmes in early and late-stage development with programme budget responsibility of $100m+ Repeatedly parachuted in to lead underperforming programmes to redefine strategic direction and improve team performance Improved team satisfaction by over 30% when took over leadership of a challenging cross-company collaboration Provided key guidance to inform business decision to end several high-risk programmes Assessment of over 100 pipeline expansion opportunities, including internal innovation and due diligence. Presentation of development strategy and business case evaluations to executive leadership team with guidance informing business portfolio strategy.
Responsible for on-time, on-budget delivery of nebuliser and nasal CDMO projects and management of department capacity aligned to demand of circa 20+ concurrent clients Leadership of Pharmaceutical Development department of over 30 FTEs.
Parachuted in to lead a high-priority device development taskforce during pivot to CDMO. Delivery of refined device strategy & team direction to meet company objectives, ensuring device performance and manufacturing capacity met client needs.
Defined and delivered drug development strategies for 4 oral phase I/II programmes. Recruitment and management of R&D team and oversight of early development work outsourced to CROs and CMOs, market research agencies and other external partners Presentations on development strategy, risks and budgets to senior management, key opinion leaders and the company Board Management of regulatory agency interactions with the MHRA and FDA informing portfolio strategy Involvement in programme out-licensing activities with international pharmaceutical companies.
Management of a regulatory compliance projects for a global pharmaceutical company, including line management of internal team of over 30 FTEs across the UK, India and Latin America.